BTSG 最新10-Q变化
将 BTSG 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-10-30 与上一份 10-Q · 2026-07-31
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +34 | −31 | ~69 | 67 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~1 | 5 |
| 控制与程序 | 文字有新增/删除 | 0 | 0 | ~1 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 公司称无重大变化(指向 10-K) | — | — | — | — |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):其他信息
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-10-30
Financial Performance Highlights: Third Quarter of 2026 Compared to Third Quarter of 2025
Pharmacy Solutions segment revenue grew by $765.5 million, or 25.8%, to $3.7 billion
Provider Services segment revenue grew by $113.7 million, or 31.0%, to $480.8 million
Net income from continuing operations increased by $63.3 million to $100.8 million
We are one of the largest independent providers of home and community-based health services in the United States, delivering both pharmacy and provider services. We believe our high-quality and complementary health services offerings address significant
相对上期删除的文字 · 来源:10-Q · 2026-07-31
$300.0 million paydown and concurrent modification of our First Lien Facility, including interest rate refinancings that resulted in interest savings
Completed an underwritten secondary offering of our common stock by affiliates Kohlberg Kravis Roberts & Co. L.P. and certain members of management in June 2026
Repurchased 1,026,465 shares of common stock in connection with the June 2026 secondary offering
Financial Performance Highlights: Second Quarter of 2026 Compared to Second Quarter of 2025
Pharmacy Solutions segment EBITDA increased by $55.4 million, or 44.4%, to $180.0 million
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议